Advertisement
Conference Call
Genesis Pharmaceuticals management will host a conference call at 9:00a.m. Eastern on Wednesday, October 1, 2008 to discuss financial results forits fourth quarter and fiscal year 2008 ended June 30, 2008. The conferencecall will include Mr. Wubo Cao, Chairman and CEO, and Ms. Elsa Sung, CFO. Toparticipate in this live conference call, please dial the following numberfive to ten minutes prior to the scheduled conference call time:(888) 419-5570. International callers should call (617) 896-9871. TheConference Passcode is 375 022 62. If you are unable to participate in thecall at that time, replay of the conference call will be available fromWednesday, October 1 at 11:00 a.m. Eastern until Wednesday, October 15. Toaccess the replay, call (888) 286-8010. International callers should call(617) 801-6888. The Conference Passcode is 31221366.
Advertisement
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engagedin the research, development, production, marketing and sales ofpharmaceutical products in the People's Republic of China. Its operations arelocated in Northeast China in an Economic Development Zone in Laiyang City,Shandong province. Genesis is a major pharmaceutical company in Chinaproducing both western and Chinese herbal-based medical drugs in tablet,capsule and granule form. The Company maintains a representative office in theU.S.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are"forward-looking statements" within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such statements are not guarantees of futureperformance and are subject to risks and uncertainties that could cause theCompany's actual results and financial position to differ materially fromthose included within the forward-looking statements. Forward-lookingstatements involve risks and uncertainties, including those relating to theCompany's ability to introduce, manufacture and distribute new drugs. Actualresults may differ materially from predicted results, and reported resultsshould not be considered as an indication of future performance. The potentialrisks and uncertainties include, among others, the Company's ability to obtainraw materials needed in manufacturing, the continuing employment of keyemployees, the failure risks inherent in testing any new drug, the possibilitythat regulatory approvals may be delayed or become unavailable, patent orlicensing concerns that may include litigation, direct competition from othermanufacturers and product obsolescence. More information about the potentialfactors that could affect the Company's business and financial results isincluded in the Company's filings, available via the United States Securitiesand Exchange Commission.Contact: Genesis Pharmaceuticals Enterprises, Inc. Ms. Elsa Sung CFO Phone: (561) 988-9880 E-mail: [email protected] http://www.genesis-china.net CCG Investor Relations, Inc. Mr. Crocker Coulson, President Phone: (646) 213-1915 E-mail: [email protected] http://www.ccgir.com
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
